Is There an Advantage to Venlafaxine in Comparison with Other Antidepressants?

Benkert, Otto; Gründer, Gerhard; Wetzel, Hermann

doi:10.1002/(sici)1099-1077(199701/02)12:1<53::aid-hup837>3.0.co;2-5

Cited by 15 publications

(15 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A more recent class of novel antidepressants blocks the reuptake of both serotonin and norepinephrine. Such dual-acting serotonin/norepinephrine reuptake inhibitors (SNRIs), including venlafaxine (Effexor), are reported to exhibit a faster clinical onset of action [3][4][5] and be more effective in treating depression that is refractory to other types of antidepressants. 6,7 Bupropion (Wellbutrin), likely by virtue of its ability to block the reuptake of norepinephrine and dopamine, has been touted as an effective antidepressant with less incidence of side effects including sexual dysfunction and weight gain.…”

Section: Introductionmentioning

confidence: 99%

Innovative approaches for the development of antidepressant drugs: Current and future strategies

Schechter¹,

Ring²,

Beyer³

et al. 2005

Neurotherapeutics

183

100

View full text Add to dashboard Cite

Summary: Depression is a highly debilitating disorder that has been estimated to affect up to 21% of the world population. Despite the advances in the treatment of depression with selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), there continue to be many unmet clinical needs with respect to both efficacy and side effects. These needs range from efficacy in treatment resistant patients, to improved onset, to reductions in side effects such as emesis or sexual dysfunction. To address these needs, there are numerous combination therapies and novel targets that have been identified that may demonstrate improvements in one or more areas. There is tremendous diversity in the types of targets and approaches being taken. At one end of a spectrum is combination therapies that maintain the benefits associated with SSRIs but attempt to either improve efficacy or reduce side effects by adding additional mechanisms (5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 2C , ␣-2A). At the other end of the spectrum are more novel targets, such as neurotrophins (BDNF, IGF), based on recent findings that antidepressants induce neurogenesis. In between, there are many approaches that range from directly targeting serotonin receptors (5-HT 2C , 5-HT 6 ) to targeting the multiplicity of potential mechanisms associated with excitatory (glutamate, NMDA, mGluR2, mGluR5) or inhibitory amino acid systems (GABA) or peptidergic systems (neurokinin 1, corticotropin-releasing factor 1, melanin-concentrating hormone 1, V1b). The present review addresses the most exciting approaches and reviews the localization, neurochemical and behavioral data that provide the supporting rationale for each of these targets or target combinations.

show abstract

Section: Introductionmentioning

confidence: 99%

Innovative approaches for the development of antidepressant drugs: Current and future strategies

Schechter¹,

Ring²,

Beyer³

et al. 2005

Neurotherapeutics

183

100

View full text Add to dashboard Cite

show abstract

“…Fluoxetine improved the performance of memory task in the response passive avoidance test and labyrinth test [Nowakowska et al, 1996]; it caused a very marked improvement of reference memory in the reference spatial memory test [Nowakowska et al, 2000;Benkert et al, 1999]; showed no effect on learning and memory but significantly reversed scopolamine-induced memory impairment on elevated-plus maze and passive avoidance tests [Kumar et al, 1996]. Citalopram and fluoxetine impaired spatial learning in the Morris water maze in rats [Majlessi and Nagndi, 2002].…”

Section: Discussionmentioning

confidence: 99%

“…Selective serotonin reuptake inhibitors (SSRIs) are as potent as antidepressants as the tricyclics and are devoid of many of the secondary effects of the latter drugs. However, SSRIs do not address all the problems inherent to the treatment of depression; since certain patients do not respond to these drugs, their antidepressant effect only becomes significant after 3-4 weeks of treatment and their use may be limited by significant drug interactions [Benkert et al, 1999]. Venlafaxine is a representative of a new class of antidepressants with unique pharmacological properties enhancing its efficacy as well as its safety profile.…”

Section: Introductionmentioning

confidence: 99%

“…It selectively inhibits the uptake of both serotonin and norepinephrine (SNRI) but shows no affinity for neurotransmitter receptors [Montgomery, 1995]. It is also devoid of the drug interactions characteristic of SSRIs [Benkert et al, 1999].…”

Section: Introductionmentioning

confidence: 99%

“…Venlafaxine is another antidepressant distinguished by marked clinical efficacy and, possibly, more rapid onset of action. Because of its lack of affinity for muscarinic, cholinergic, a 1 -adrenergic, and histaminergic receptors, its safety profile is superior to that of TCAs [Benkert et al, 1999]. A large number of contradictory findings exist regarding the effects of these drugs on memory processes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Chronic administration of fluoxetine or venlafaxine induces memory deterioration in an inhibitory avoidance task in rats

Ulak

Göçmez

Erden

et al. 2006

Drug Development Research

View full text Add to dashboard Cite

Antidepressants inhibiting the reuptake of both serotonin and norepinephrine may exhibit efficacy superior to that of selective serotonin reuptake inhibitors (SSRIs). Since the clinical effects of antidepressants appear gradually following weeks of treatment, the present study was designed to investigate if there is a benefit to long-term administration of the SSRI, fluoxetine, in comparison with venlafaxine, a 5-HT/norepinephrine (5-HT/NE) reuptake inhibitor (SNRI; both 20 mg/kg ip, once a day for 14 days) in a one-trial step-through passive avoidance task in rats. Locomotor activity was evaluated to assess the effects of the drugs on the motility of the animals. The comparison of training latencies versus test latencies showed inhibition of passive avoidance learning in fluoxetine-or venlafaxine-treated rats (e.g., no significant difference between training and test latencies) in a step-through test. There was no significant difference between fluoxetine-and venlafaxine-induced reduction of latency in rats in this test. Drug Dev.

show abstract

Antidepressiva

Holsboer‐Trachsler¹,

Holsboer²

Handbuch Der Psychopharmakotherapie

View full text Add to dashboard Cite

Is There an Advantage to Venlafaxine in Comparison with Other Antidepressants?

Cited by 15 publications

References 48 publications

Innovative approaches for the development of antidepressant drugs: Current and future strategies

Innovative approaches for the development of antidepressant drugs: Current and future strategies

Chronic administration of fluoxetine or venlafaxine induces memory deterioration in an inhibitory avoidance task in rats

Antidepressiva

Contact Info

Product

Resources

About